Market Wire – AVI BioPharma Opens Investigational New Drug (IND) Application for AVI-4658 in Duchenne Muscular Dystrophy
July 7, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that following review by the U.S. Food and Drug…
More: continued here
Filed under Acne Treatments by on Jul 10th, 2010.
Leave a Comment